Portal de Periódicos da CAPES

Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study

2021; Elsevier BV; Volume: 229; Linguagem: Inglês

10.1016/j.clim.2021.108786

1521-7035

Miguel García‐Grimshaw, Santa Elizabeth Ceballos‐Liceaga, Laura E. Hernández‐Vanegas, Isaac Núñez, Noé Hernández-Valdivia, Daniel Amado Carrillo-García, Anaclara Michel‐Chávez, Javier Andrés Galnares‐Olalde, Guillermo Carbajal‐Sandoval, María del Mar Saniger‐Alba, Roger Carrillo‐Mezo, Sergio Fragoso-Saavedra, Alba Espino-Ojeda, Carlos Blaisdell-Vidal, Juan Luis Mosqueda-Gómez, Juan Sierra‐Madero, Rogelio Pérez‐Padilla, José Luis Alomía-Zegarra, Hugo López‐Gatell, José Luis Díaz‐Ortega, Gustavo Reyes‐Terán, Antonio Araúz, Sergio Iván Valdés‐Ferrer,

Long-Term Effects of COVID-19

mRNA vaccines against SARS-CoV-2 are remarkably effective. Limited information exists about the incidence of adverse events following immunization (AEFI) with their use. We conducted a prospective observational study including data from 704,003 first-doses recipients; 6536 AEFI were reported, of whom 65.1% had at least one neurologic AEFI (non-serious 99.6%). Thirty-three serious events were reported; 17 (51.5%) were neurologic (observed frequency, 2.4/100,000 doses). At the time of writing this report, 16/17 cases had been discharged without deaths. Our data suggest that the BNT162b2 mRNA COVID-19 vaccine is safe; its individual and societal benefits outweigh the low percentage of serious neurologic AEFI. This information should help to dissipate hesitancy towards this new vaccine platform.